Dr. Charles Link recently discussed the innovative SYNC-T technology (Syncromune® Inc.) during a phase one trial targeting hormone-refractory prostate cancer—a…
Introduction to Emerging Therapies in ALL Management … Dr. Elias Jabbour shared recent developments in the treatment of acute lymphoblastic…
… The field of oncology is continuously evolving, with research focusing on developing more effective and personalized treatment modalities. One…
… Pancreatic cancer, notorious for its lethality and late-stage diagnosis, presents significant challenges in oncological treatment and patient survival. Dr.…
… Lung cancer remains the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for the…
… Multiple myeloma, an incurable cancer affecting plasma cells in the bone marrow, continues to challenge the medical community. The…
… Introduction Small cell lung cancer (SCLC) is notoriously aggressive and challenging to treat, with current therapies often providing limited…
… The recent approval by the Food and Drug Administration (FDA) of ponatinib (ICLUSIG®) in combination with chemotherapy represents a…
… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set a benchmark in oncology, providing…
The MOASC represents a prestigious accolade designed to recognize and encourage promising young researchers in the field of oncology. This…
… At the MOASC Annual Oncology Summit & Research Symposium, Dr. Karen Reckamp, MD, MS, a leading figure in medical…
… Melanoma treatment has significantly evolved due to extensive research and the introduction of novel therapeutic options. Dr. Justin T.…
… The field of oncology is witnessing a paradigm shift in the treatment of lymphomas, fueled by the emergence of…
… Introduction to ADCs in Cancer Therapy The advent of targeted therapies has revolutionized the field of oncology, offering new…
… In the rapidly evolving field of oncology, colorectal cancer (CRC) represents a significant area of research and clinical development.…
… [VIDEO & SLIDES] Alex Chehrazi –Raffle, MD, City of Hope – 2024 MOASC Annual Oncology Summit & Research Symposium…
… [VIDEO with 39 SLIDES] – Dr. Rebecca Shatsky, MD from the 2024 MOASC Annual Oncology Summit & Research Symposium…
Overview The U.S. Food and Drug Administration (FDA) has granted approval for the use of inotuzumab ozogamicin (Besponsa, Pfizer) in…
On March 7, 2024, the Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib, marketed as Brukinsa by BeiGene…
The FDA granted Priority Review of the supplemental Biologics License Application (sBLA) for epcoritamab-bysp. This subcutaneously administered T-cell engaging bispecific…
Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set of challenges for both patients…
Zahra Pakbaz, MD, shed light on a range of critical findings from the American Society of Hematology (ASH) meeting, with…
In 2024, CAR T-cell therapy continues to transform the landscape of treatment for hematologic malignancies, including multiple myeloma and various…
ASH Groundbreaking Trials and Therapies Transform Multiple Myeloma Treatment The recent American Society of Hematology (ASH) meeting showcased significant advancements…
Assessing the Impact of COVID-19 on Cancer Screening and Diagnosis Rates in the United States: A 2020 Overview The COVID-19…
March 1, 2024 – In a significant advancement for lung cancer treatment, the Food and Drug Administration (FDA) has approved…
A New Horizon in Gene Editing In the rapidly evolving field of genetic medicine, a groundbreaking development has emerged with…
The battle against polycythemia vera (PV), a rare and chronic form of blood cancer, has seen a transformative advancement with…
On February 15, 2024, the Food and Drug Administration (FDA) approved tepotinib, commercially known as Tepmetko®, for its use in…
Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews Below) On February 20th, 2024…
What is the new treatment for metastatic melanoma? On February 16, 2024, the medical community witnessed a significant milestone in…
On February 16, 2024, the Food and Drug Administration (FDA) announced the approval of osimertinib, marketed under the brand name…
We asked 5 top KOLS at ASCO GI 2024 the same questions on MRD and CTDNA testing. You might be…
… Anup Kasi, MD, Associate Professor and Vice Chair of GI Oncology at the University of Kansas Medical Center, is…
Suneel Kamath, MD: [00:00:00] So this this trial that the tech 24 trial was really looking at a pan G.…
Van K. Morris, MD: [00:00:00] Thanks Allen for for having me and letting me represent our team of investigators who…
Naureen Starling, MD: [00:00:00] Of course. So AZUR-2, as you said, is a global study. Open label, randomized, running in…
Sakti Chakrabarti, MD: [00:00:00] So Dream GI is a national database through which we collect data on localized GI cancer…
Michael Weickert, PhD: [00:00:00] So the first thing I want to explain is Zelenirstat is a first in class therapy…
Thejus Jayakrishnan, MD: [00:00:00] Those of you who have listened to the keynote address today by Dr. Ng from Dana…
Sawyer Bawek, MD: So in colorectal cancer with liver metastasis, studies have shown that immunotherapy has a poor response on…
Anup Kasi, MD: [00:00:00] So this is an investigative initiated trial called the EPIC trial. Where we’re investigating n fotamibidotin,…
Simron Singh, MD: [00:00:00] So radioligand therapy is like in a new emerging treatment for cancer. where we try to…
Howard S. Hochster, MD: [00:00:00] Um, first of all, this is for late line colorectal cancer after the standard chemotherapy…
OncologyTube: [00:00:00] Okay. We’re here at ASCO GI 2024. And, we have the honor of, having Dr. Christopher Lieu, MD…
OncologyTube: [00:00:00] Okay, here we are at ASCO GI 2024. We have Dominik Paul Modest, MD medical doctor from Charite,University…
OncologyTube: [00:00:00] Okay. Okay, we’re here at ASCO GI 2024 and we have Dr. Anthony B. El-Khoueiry, MD a medical…
OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Dr. Dr. Riccardo Lencioni, MD medical doctor, professor…
OncologyTube: [00:00:00] We have Dr. Milind Javle, MD. He is from the Department of Gastrointestinal Medical Oncology at the University…
OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Jeanne Tie, MD a medical doctor, the medical…